Primary Sclerosing Cholangitis (PSC) Market

DelveInsight’s ‘Primary Sclerosing Cholangitis (PSC) Market Insights, Epidemiology, and Market Forecast – 2032’ report deliver an in-depth understanding of the Primary Sclerosing Cholangitis, historical and forecasted epidemiology as well as the market trends in the United States, the EU-5 (Germany, Spain, Italy, France, and United Kingdom), Nordic countries (Sweden, Finland, Denmark, and Norway), and Japan.

 

The Primary Sclerosing Cholangitis market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted Primary Sclerosing Cholangitis symptoms market size from 2019 to 2032 segmented by the seven major markets + Nordic countries. The report also covers current Primary Sclerosing Cholangitis symptoms, diagnostic and treatment practice guidelines/algorithms and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.

 

Geography Covered

  • The United States
  • The EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Nordic countries (Sweden, Finland, Denmark, and Norway)
  • Japan

Study Period: 2019–2032

Primary Sclerosing Cholangitis Disease Background and Treatment Algorithm

Primary Sclerosing Cholangitis (PSC) Overview

Primary sclerosing cholangitis (PSC) is a rare progressive disorder characterized by inflammation, thickening, and abnormal formation of fibrous tissue (fibrosis) within the passages that carry bile from the liver (bile ducts). Both the bile ducts within the liver (intrahepatic) and outside the liver (extrahepatic) are affected, resulting in the obstruction or interruption of bile flow from the liver (cholestasis).

 

Primary Sclerosing Cholangitis Diagnosis and Treatment

This section covers the details of conventional and current medical therapies and diagnoses available in the Primary Sclerosing Cholangitis market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, the EU-5, Nordic countries, and Japan.

 

DelveInsight’s Primary Sclerosing Cholangitis market report thoroughly understands Primary Sclerosing Cholangitis symptoms by including disease definition, symptoms, causes, physiology, and diagnosis. It also provides Primary Sclerosing Cholangitis treatment algorithms and treatment guidelines for Primary Sclerosing Cholangitis symptoms in the US, the EU-5, Nordic countries, and Japan.

 

High-dose ursodeoxycholic acid is used to treat PSC patients with a trend toward increased survival. Dominant bile duct stenoses should be treated endoscopically. However, liver transplantation is the only therapeutic option for patients with advanced disease.

 

A few major unmet needs in the market include lack of effective therapies, lack of proven surveillance strategies, lack of tools for early detection of malignancies, impact on quality of life (QoL), and lack of surrogate endpoints in clinical trials, among others.

Primary Sclerosing Cholangitis Epidemiology

The Primary Sclerosing Cholangitis symptoms epidemiology division provides insights into the historical and current patient pool and the forecasted trend for every seven major countries + Nordic countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of KOL. This part of the DelveInsight report also provides the diagnosed patient pool and their trends and assumptions.

 

Key Findings

The total diagnosed prevalent cases of Primary Sclerosing Cholangitis  patients in the 7MM + Nordic countries are increasing during the study period, i.e., 2019–2032.

 

The disease epidemiology covered in the report provides historical as well as forecasted Primary Sclerosing Cholangitis epidemiology segmented as the total diagnosed prevalent cases of Primary Sclerosing Cholangitis, gender-specific cases of Primary Sclerosing Cholangitis, comorbidity-specific cases of Primary Sclerosing Cholangitis, and symptom-specific cases of Primary Sclerosing Cholangitis. The report includes the diagnosed prevalent cases scenario of Primary Sclerosing Cholangitis in the 7MM + Nordic countries covering the United States, the EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), Nordic countries (Sweden, Finland, Denmark, and Norway), and Japan from 2019 to 2032.

Primary Sclerosing Cholangitis (PSC) Epidemiology

 

Country-wise Primary Sclerosing Cholangitis Epidemiology

  • The epidemiology segment also provides the Primary Sclerosing Cholangitis epidemiology data and findings across the United States, the EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Nordic countries (Sweden, Finland, Denmark, and Norway), and Japan.
  • The total number of diagnosed prevalent cases of Primary Sclerosing Cholangitis associated in the 7MM countries + Nordic countries was approximately 59,000 in 2021.
  • Primary Sclerosing Cholangitis Drug Chapters
  • The Primary Sclerosing Cholangitis report’s drug chapter segment encloses the detailed analysis of Primary Sclerosing Cholangitis early-stage (Phase I, II, and III) pipeline drugs. It also helps understand the Primary Sclerosing Cholangitis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

 

Primary Sclerosing Cholangitis Emerging Drugs

Cilofexor: Gilead Sciences/Phenex Pharmaceuticals

Cilofexor (GS-9674) is a potent, selective, orally active, nonsteroidal FXR agonist. It is an investigational agent to treat primary sclerosing cholangitis (PSC), a chronic cholestatic liver disease with limited treatment options for patients and significant unmet needs. Synthetic FXR agonists reduce potentially toxic levels of bile acids in the liver and enterohepatic circulation, display anti-inflammatory properties, reduce portal hypertension, and diminish gut permeability.

 

Currently, Cilofexor is undergoing evaluation in the Phase III PRIMIS study to evaluate the safety, tolerability, and efficacy of Cilofexor in non-cirrhotic subjects with PSC at multiple locations worldwide.

 

HTD 1801: HighTide Therapeutics

HTD1801 is a first-in-class new molecular entity and is an ionic salt of two active moieties, berberine and ursodeoxycholic acid. It is administered orally, acts as a lipid modulator, and significantly reduces liver fat.

 

It has completed a Phase II trial to treat PSC and is currently under Phase II trials for other chronic disorders.

Other Products detailed in the report…

Primary Sclerosing Cholangitis (PSC) Market

Primary Sclerosing Cholangitis Market Outlook

The report’s Primary Sclerosing Cholangitis market outlook helps understand historic, current, and forecasted Primary Sclerosing Cholangitis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

 

This segment gives a thorough detail of the Primary Sclerosing Cholangitis market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the KOL. The calculated market data are presented with relevant tables and graphs to glance the market at first sight.

 

According to DelveInsight, Primary Sclerosing Cholangitis market in the 7MM + Nordic countries is expected to grow steadily during the study period (2019–2032).

 

High-dose ursodeoxycholic acid is used to treat PSC patients due to a trend toward increased survival. Dominant bile duct stenoses should be treated endoscopically. However, liver transplantation is the only therapeutic option for patients with advanced disease. Patients have significant unmet needs due to limited therapeutic options and a lack of proven surveillance strategies.

 

The major market players in the Primary Sclerosing Cholangitis therapeutic market are Dr. Falk Pharma, HighTide Biopharma, and Gilead Sciences, among others.

 

Key Findings

This section includes a glimpse of the Primary Sclerosing Cholangitis market in the 7MM + Nordic countries. The primary Sclerosing Cholangitis market size in the seven major markets + Nordic countries was approximately USD 900 million in 2021.

 

The United States Market Outlook

This section provides the total Primary Sclerosing Cholangitis market size and market size by therapies in the United States.

 

The United States accounts for the largest market size of Primary Sclerosing Cholangitis compared to the EU-5 (the United Kingdom, Germany, Italy, France, and Spain), Nordic countries (Sweden, Finland, Denmark, and Norway), and Japan.

 

The EU-5 Countries: Market Outlook

The total Primary Sclerosing Cholangitis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Nordic Countries: Market Outlook

The total Primary Sclerosing Cholangitis market size and market size by therapies in Sweden, Finland, Denmark, and Norway are provided in this section.

 

Japan Market Outlook

The total Primary Sclerosing Cholangitis market size and market size by therapies in Japan are also mentioned.

Primary Sclerosing Cholangitis (PSC) Market Share

 

Primary Sclerosing Cholangitis Drugs Uptake

This section focuses on the uptake of the potential drugs recently launched or expected to be launched in the market during 2019–2032. The analysis covers the Primary Sclerosing Cholangitis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

 

This helps understand the drugs with the most rapid uptake, the reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

 

Primary Sclerosing Cholangitis Pipeline Development Activities

The report provides insights into the therapeutic candidate in Phase I, II, and III stages. It also analyses Primary Sclerosing Cholangitis key players in developing targeted therapeutics.

 

Major market players include Dr. Falk Pharma, HighTide Biopharma, and Gilead Sciences, among others.

 

Pipeline Development Activities

The report covers detailed information on collaborations, acquisitions, mergers, licensing, and patent details for Primary Sclerosing Cholangitis emerging therapies.

 

In October 2018, Gilead Sciences announced that the US FDA had granted Orphan Drug Designation to Cilofexor to treat PSC.

 

Reimbursement Scenario in Primary Sclerosing Cholangitis 

Proactively approaching reimbursement can positively impact both during the early stages of product development and after product launch. The report considers reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with better market access can be a critical business and price strategy.

 

High-dose ursodeoxycholic acid is used to treat PSC patients because of a trend toward increased survival. Dominant bile duct stenosis should be treated endoscopically. However, liver transplantation continues to be the only therapeutic option for patients with advanced disease.

 

Besides this, immunosuppressive-based therapies such as glucocorticoids, azathioprine, tacrolimus, and a few others are in use, especially in patients with additional autoimmune hepatitis (AIH) or IgG4-related sclerosing cholangitis (IgG4-SC).

 

Liver transplants in the UK are much more affordable than in the US. As the healthcare sector is highly regulated, most transplants are successful. Most patients spend at least 2 weeks in the hospital after the operation. Private health plans do not pay for transplants, but it costs the NHS up to 80,000 USD plus several thousand extras, depending on the stability of the recovery period.

 

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in the Primary Sclerosing Cholangitis (PSC) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or Primary Sclerosing Cholangitis (PSC) market trends. This will support the clients in potential novel treatments by identifying the overall scenario of the market and the unmet needs.

 

Competitive Intelligence Analysis

We perform a competitive and market intelligence analysis of the Primary Sclerosing Cholangitis (PSC) Market using various competitive intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, and market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

 

Report Metrics

Details

Study Period

2019 to 2032

Base Year

2021

Forecast Period

2022 to 2032

CAGR

Request Sample to Know

Market Size

USD 900 Billion in 2021

Key Companies

Gilead Sciences, Phenex Pharmaceuticals, HighTide Therapeutics, Dr. Falk Pharma, Mirum Pharmaceuticals, Pliant Therapeutics, Inc, NGM Biopharmaceuticals, CymaBay Therapeutics, Chemomab Therapeutics, and others

Scope of the Report

  • The report covers the descriptive overview of Primary Sclerosing Cholangitis (PSC), explaining its causes, signs and symptoms, physiology, and currently available therapies
  • Comprehensive insight has been provided into the Primary Sclerosing Cholangitis (PSC) epidemiology and treatment in the 7MM + Nordic countries
  • Additionally, an all-inclusive account of the current and emerging therapies for Primary Sclerosing Cholangitis (PSC) is provided, along with the assessment of new therapies which will impact the current treatment landscape
  • A detailed review of the Primary Sclerosing Cholangitis (PSC) market, historical and forecasted, is included in the report, covering drug outreach in the 7MM + Nordic countries
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Primary Sclerosing Cholangitis (PSC) market

 

Report Highlights

  • In the coming years, the Primary Sclerosing Cholangitis (PSC) market is set to change due to the rising awareness of the disease, the development of diagnostic techniques, and the favorable environment from regulators for innovative first-in-class curative drugs, which are likely to expand the market’s size and enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Primary Sclerosing Cholangitis (PSC) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Primary Sclerosing Cholangitis (PSC). Launching emerging therapies will significantly impact the Primary Sclerosing Cholangitis (PSC) market
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase I, II, and III), other emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, and launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

 

Primary Sclerosing Cholangitis (PSC) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Primary Sclerosing Cholangitis (PSC)  Pipeline Analysis
  • Primary Sclerosing Cholangitis (PSC)  Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

 

Primary Sclerosing Cholangitis (PSC) Report Key Strengths

  • 11-Year Forecast
  • 7MM + Nordic Countries Coverage
  • Primary Sclerosing Cholangitis (PSC) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

 

Primary Sclerosing Cholangitis (PSC) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness

 

Key Questions

Market Insights:

  • What was the Primary Sclerosing Cholangitis (PSC) market share percentage distribution in 2019, and how would it look by 2032?
  • What would be the Primary Sclerosing Cholangitis (PSC) total market size and market size by therapies across the 7MM + Nordic countries during the forecast period (2019–2032)?
  • What are the key findings of the market across the 7MM + Nordic countries, and which country will have the largest Primary Sclerosing Cholangitis (PSC) market size during the forecast period (2019–2032)?
  • At what CAGR the Primary Sclerosing Cholangitis (PSC) market is expected to grow in the 7MM + Nordic countries during the forecast period (2019–2032)?
  • What would be the Primary Sclerosing Cholangitis (PSC) market outlook across the 7MM + Nordic countries during the forecast period (2019–2032)?
  • What would be the Primary Sclerosing Cholangitis (PSC) market growth till 2032, and what will be the resultant market size by 2032?

 

Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of Primary Sclerosing Cholangitis (PSC)?
  • What is the historical Primary Sclerosing Cholangitis (PSC) patient pool in the 7MM + Nordic countries covering the United States, the  EU5 (Germany, Spain, France, Italy, the UK), Nordic countries (Sweden, Finland, Denmark, and Norway), and Japan?
  • What would be the forecasted patient pool of Primary Sclerosing Cholangitis (PSC)  in the 7MM + Nordic countries covering the United States, the EU5 (Germany, Spain, France, Italy, the UK), Nordic countries (Sweden, Finland, Denmark, and Norway), and Japan?
  • What will be the growth opportunities in the 7MM + Nordic countries concerning the patient population for Primary Sclerosing Cholangitis (PSC)?
  • Among the 7MM + Nordic countries, which country would have the largest diagnosed prevalent population of Primary Sclerosing Cholangitis (PSC) during the forecast period (2019–2032)?
  • At what CAGR is the population expected to grow in the 7MM + Nordic countries during the forecast period (2019–2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for treating Primary Sclerosing Cholangitis (PSC) along with the approved therapy?
  • What are the current treatment guidelines for treating Primary Sclerosing Cholangitis (PSC) in the US, the EU5, Nordic countries, and Japan?
  • What are the Primary Sclerosing Cholangitis (PSC) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for treating Primary Sclerosing Cholangitis (PSC)?
  • How many therapies are developed by each company to treat Primary Sclerosing Cholangitis (PSC)?
  • How many emerging therapies are in the mid-stage and late stages of development to treat Primary Sclerosing Cholangitis (PSC)?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, and licensing activities related to Primary Sclerosing Cholangitis (PSC) therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Primary Sclerosing Cholangitis (PSC) and their status?
  • What key designations have been granted for the emerging therapies for Primary Sclerosing Cholangitis (PSC)?
  • What are the global historical and forecasted markets for Primary Sclerosing Cholangitis (PSC)?

 

Reasons to buy

  • The report will help develop business strategies by understanding trends shaping and driving the Primary Sclerosing Cholangitis (PSC) market
  • To understand the future market competition in the Primary Sclerosing Cholangitis (PSC) market and an Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Primary Sclerosing Cholangitis (PSC) in the US, the EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Nordic countries (Sweden, Finland, Denmark, and Norway), and Japan
  • Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for the Primary Sclerosing Cholangitis (PSC) market
  • To understand the future market competition in the Primary Sclerosing Cholangitis (PSC) market

1. Key Insights

2. Report Introduction

3. Primary Sclerosing Cholangitis (PSC) Market Overview at a Glance

3.1. Market Share Percentage Distribution of Primary Sclerosing Cholangitis (PSC) in 2019

3.2. Market Share Percentage Distribution of Primary Sclerosing Cholangitis (PSC) in 2032

4. Executive Summary of Primary Sclerosing Cholangitis (PSC)

5. Disease Background and Overview

5.1. Introduction

5.2. Classification of Sclerosing Cholangitis

5.3. Clinical Phenotypes

5.4. Clinical Manifestations

5.5. Etiology and Risk Factors

5.6. Pathogenesis

5.7. Malignant Diseases Associated With PSC

5.8. Complications Associated With PSC

5.9. Diagnosis

5.10. Treatment

5.11. Clinical Practice Guidelines

5.11.1. Diagnostic Guidelines

5.11.1.1. American College of Gastroenterology (ACG) Guidelines

5.11.1.2. American Association for the Study of Liver Diseases (AASLD)

5.11.1.3. British Society of Gastroenterology and UK-PSC Guidelines for PSC diagnosis

5.11.2. Treatment Guidelines

5.11.2.1. American Association for the Study of Liver Diseases (AASLD)

5.11.2.2. American College of Gastroenterology (ACG) Guidelines

5.11.2.3. British Society of Gastroenterology and UK-PSC guidelines for the management of PSC

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM + Nordic Countries Total Diagnosed Prevalent Population of Primary Sclerosing Cholangitis

6.3. The United States

6.3.1. Total Diagnosed Prevalent Cases of Primary Sclerosing Cholangitis (PSC) in the United States

6.3.2. Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in the United States

6.3.3. Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in the United States

6.3.4. Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in the United States

6.4. The EU-5

6.4.1. Total Diagnosed Prevalent Cases of Primary Sclerosing Cholangitis (PSC) in the EU-5

6.4.2. Germany

6.4.2.1. Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Germany

6.4.2.2. Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Germany

6.4.2.3. Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Germany

6.4.3. France

6.4.3.1. Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in France

6.4.3.2. Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in France

6.4.3.3. Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in France

6.4.4. Italy

6.4.4.1. Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Italy

6.4.4.2. Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Italy

6.4.4.3. Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Italy

6.4.5. Spain

6.4.5.1. Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Spain

6.4.5.2. Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Spain

6.4.5.3. Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Spain

6.4.6. The United Kingdom

6.4.6.1. Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in the United Kingdom

6.4.6.2. Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in the United Kingdom

6.4.6.3. Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in the United Kingdom

6.5. Nordic Countries

6.5.1. Total Diagnosed Prevalent Cases of Primary Sclerosing Cholangitis (PSC) in Nordic Countries

6.5.2. Sweden

6.5.2.1. Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Sweden

6.5.2.2. Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Sweden

6.5.2.3. Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Sweden

6.5.3. Finland

6.5.3.1. Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Finland

6.5.3.2. Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Finland

6.5.3.3. Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Finland

6.5.4. Denmark

6.5.4.1. Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Denmark

6.5.4.2. Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Denmark

6.5.4.3. Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Denmark

6.5.5. Norway

6.5.5.1. Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Norway

6.5.5.2. Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Norway

6.5.5.3. Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Norway

6.6. Japan

6.6.1. Total Diagnosed Prevalent Cases of Primary Sclerosing Cholangitis (PSC) in Japan

6.6.2. Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Japan

6.6.3. Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Japan

6.6.4. Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Japan

7. Patient Journey

8. Emerging Therapies

8.1. Key Cross Competition

8.2. Cilofexor: Gilead Sciences/Phenex Pharmaceuticals

8.2.1. Drug description

8.2.2. Regulatory milestones

8.2.3. Other development activities

8.2.4. Clinical development

8.2.4.1. Clinical trial information

8.2.5. Safety and efficacy

8.2.6. Product profile

8.2.7. Analyst views

8.3. Norursodeoxycholic acid: Dr. Falk Pharma

8.3.1. Drug description

8.3.2. Other development activities

8.3.3. Clinical development

8.3.3.1. Clinical trials information

8.3.4. Safety and efficacy

8.3.5. Product profile

8.3.6. Analyst views

8.4. HTD1801: HighTide Therapeutics

8.4.1. Drug description

8.4.2. Regulatory milestones

8.4.3. Other development activities

8.4.4. Clinical development

8.4.4.1. Clinical trial information

8.4.5. Safety and efficacy

8.4.6. Product profile

8.4.7. Analyst views

8.5. Volixibat: Mirum Pharmaceuticals

8.5.1. Drug description

8.5.2. Other development activities

8.5.3. Clinical development

8.5.3.1. Clinical trial information

8.5.4. Product profile

8.5.5. Analyst views

9. Other Promising Therapies

9.1. Other Assets

9.2. PLN-74809: Pliant Therapeutics, Inc.

9.2.1. Drug description

9.2.2. Other development activities

9.2.3. Clinical development

9.2.3.1. Clinical trial information

9.2.4. Product profile

9.3. Aldafermin (NGM282): NGM Biopharmaceuticals

9.3.1. Drug description

9.3.2. Other development activities

9.3.3. Clinical development

9.3.3.1. Clinical trial information

9.3.4. Safety and efficacy

9.3.5. Product profile

9.4. Seladelpar: CymaBay Therapeutics

9.4.1. Drug description

9.4.2. Other development activities

9.4.3. Clinical development

9.4.3.1. Clinical trial information

9.4.4. Product Profile

9.5. CM-101: Chemomab Therapeutics

9.5.1. Drug description

9.5.2. Regulatory milestones

9.5.3. Other development activities

9.5.4. Clinical development

9.5.4.1. Clinical trial information

9.5.5. Safety and efficacy

9.5.6. Product profile

10. Primary Sclerosing Cholangitis (PSC): Seven Major Markets + Nordic Countries Market Analysis

10.1. Key Findings

10.2. 7MM + Nordic Countries Market Size of Primary Sclerosing Cholangitis (PSC)

10.3. Market Outlook

10.4. Attribute Analysis

10.5. The United States Market Size

10.5.1. Total Market Size of Primary Sclerosing Cholangitis (PSC) in the United States

10.5.2. Market Size of Primary Sclerosing Cholangitis (PSC) by Therapies

10.6. The EU-5 Market

10.6.1. Total Market Size of Primary Sclerosing Cholangitis (PSC) in the EU-5

10.6.2. Germany

10.6.2.1. Market Size of Primary Sclerosing Cholangitis (PSC) by Therapies in Germany

10.6.3. France

10.6.3.1. Market Size of Primary Sclerosing Cholangitis (PSC) by Therapies in France

10.6.4. Italy

10.6.4.1. Market Size of Primary Sclerosing Cholangitis (PSC) by Therapies in Italy

10.6.5. Spain

10.6.5.1. Market Size of Primary Sclerosing Cholangitis (PSC) by Therapies in Spain

10.6.6. United Kingdom

10.6.6.1. Market Size of Primary Sclerosing Cholangitis (PSC) by Therapies in the United Kingdom

10.7. Nordic Countries

10.7.1. Total Market Size of Primary Sclerosing Cholangitis (PSC) in Nordic Countries

10.7.2. Sweden

10.7.2.1. Market Size of Primary Sclerosing Cholangitis (PSC) by Therapies in Sweden

10.7.3. Finland

10.7.3.1. Market Size of Primary Sclerosing Cholangitis (PSC) by Therapies in Finland

10.7.4. Denmark

10.7.4.1. Market Size of Primary Sclerosing Cholangitis (PSC) by Therapies in Denmark

10.7.5. Norway

10.7.5.1. Market Size of Primary Sclerosing Cholangitis (PSC) by Therapies in Norway

10.8. Japan

10.8.1. Total Market Size of Primary Sclerosing Cholangitis (PSC) in Japan

10.8.2. Market Size of Primary Sclerosing Cholangitis (PSC) by Therapies in Japan

11. SWOT Analysis

12. Unmet Needs

13. KOL Views

14. Market Access and Reimbursement

14.1. Healthcare resource utilization

14.2. The US

14.3. Health Technology Assessment

14.3.1. National Institute for Health and Care Excellence (NICE)

14.3.2. Scandiatransplant

15. Acronyms and Abbreviations

16. Appendix

16.1. Bibliography

16.2. Report Methodology

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

List of Table

Table 1: Summary of Primary Sclerosing Cholangitis (PSC), Market, Epidemiology, and Key Events (2019–2032)

Table 2: Phenotypic Variants of PSC

Table 3: 7MM + Nordic Countries Total Diagnosed Prevalent Population of Primary Sclerosing Cholangitis (PSC) (2019–2032)

Table 4: Total Diagnosed Prevalent Cases of Primary Sclerosing Cholangitis (PSC) in the United States (2019–2032)

Table 5: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in the United States (2019–2032)

Table 6: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in the United States (2019–2032)

Table 7: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in the United States (2019–2032)

Table 8: Total Diagnosed Prevalent Cases of Primary Sclerosing Cholangitis (PSC) in the EU-5 (2019–2032)

Table 9: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Germany (2019–2032)

Table 10: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Germany (2019–2032)

Table 11: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Germany (2019–2032)

Table 12: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in France (2019–2032)

Table 13: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in France (2019–2032)

Table 14: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in France (2019–2032)

Table 15: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Italy (2019–2032)

Table 16: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Italy (2019–2032)

Table 17: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Italy (2019–2032)

Table 18: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Spain (2019–2032)

Table 19: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Spain (2019–2032)

Table 20: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Spain (2019–2032)

Table 21: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in the United Kingdom (2019–2032)

Table 22: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in the United Kingdom (2019–2032)

Table 23: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in the United Kingdom (2019–2032)

Table 24: Total Diagnosed Prevalent Cases of  Primary Sclerosing Cholangitis (PSC) in Nordic Countries (2019–2032)

Table 25: Gender-specific Cases of  Primary Sclerosing Cholangitis (PSC) in Sweden (2019–2032)

Table 26: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Sweden (2019–2032)

Table 27: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Sweden (2019–2032)

Table 28: Gender-specific Cases of  Primary Sclerosing Cholangitis (PSC) in Finland (2019–2032)

Table 29: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Finland (2019–2032)

Table 30: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Finland (2019–2032)

Table 31: Gender-specific Cases of  Primary Sclerosing Cholangitis (PSC) in Denmark (2019–2032)

Table 32: Comorbidities-specific Cases of Primary Sclerosing Cholangitis (PSC) in Denmark (2019–2032)

Table 33: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Denmark (2019–2032)

Table 34: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Norway (2019–2032)

Table 35: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Norway (2019–2032)

Table 36: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Norway (2019–2032)

Table 37: Total Diagnosed Prevalent Cases of  Primary Sclerosing Cholangitis (PSC) in Japan (2019–2032)

Table 38: Gender-specific Cases of  Primary Sclerosing Cholangitis (PSC) in Japan (2019–2032)

Table 39: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Japan (2019–2032)

Table 40: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Japan (2019–2032)

Table 41: Cilofexor, Clinical Trial Description, 2022

Table 42: norUDCA, Clinical Trial Description, 2022

Table 43: HTD1801, Clinical Trial Description, 2022

Table 44: Volixibat, Clinical Trial Description, 2022

Table 45: PLN-74809, Clinical Trial Description, 2022

Table 46: Aldafermin, Clinical Trial Description, 2022

Table 47: Seladelpar, Clinical Trial Description, 2022

Table 48: CM-101, Clinical Trial Description, 2022

Table 49: 7MM + Nordic Countries Market Size of Primary Sclerosing Cholangitis (PSC) in USD Million (2019–2032)

Table 50: Attribute analysis of Emerging drugs

Table 51: Total Market Size of Primary Sclerosing Cholangitis (PSC) in the United States in USD million (2019–2032)

Table 52: Market Size of Primary Sclerosing Cholangitis (PSC) in the United States by Therapies in USD million (2019–2032)

Table 53: Total Market Size of Primary Sclerosing Cholangitis (PSC) in the EU-5 in USD million (2019–2032)

Table 54: Market Size of Primary Sclerosing Cholangitis (PSC) in Germany by Therapies in USD million  (2019–2032)

Table 55: Market Size of Primary Sclerosing Cholangitis (PSC) in France by Therapies in USD million (2019–2032)

Table 56: Market Size of Primary Sclerosing Cholangitis (PSC) in Italy by Therapies in USD million (2019–2032)

Table 57: Market Size of Primary Sclerosing Cholangitis (PSC) in Spain by Therapies in USD million (2019–2032)

Table 58: Market Size of Primary Sclerosing Cholangitis (PSC) in the United Kingdom by Therapies in USD million (2019–2032)

Table 59: Total Market Size of Primary Sclerosing Cholangitis (PSC) in Nordic Countries in USD million (2019–2032)

Table 60: Market Size of Primary Sclerosing Cholangitis (PSC) in Sweden by Therapies in USD million (2019–2032)

Table 61: Market Size of Primary Sclerosing Cholangitis (PSC) in Finland by Therapies in USD million (2019–2032)

Table 62: Market Size of Primary Sclerosing Cholangitis (PSC) in Denmark by Therapies in USD million (2019–2032)

Table 63: Market Size of Primary Sclerosing Cholangitis (PSC) in Norway by Therapies in USD million (2019–2032)

Table 64: Total Market Size of Primary Sclerosing Cholangitis (PSC) in Japan in USD million (2019–2032)

Table 65: Market Size of Primary Sclerosing Cholangitis (PSC) in Japan by Therapies in USD million  (2019–2032)

Table 66: Cost of Liver Transplantation

List of Figures

Figure 1: Types of Sclerosing Cholangitis

Figure 2: Risk Factors Involved in PSC

Figure 3: Pathogenesis of PSC

Figure 4: Diagnostic Algorithm

Figure 5: Algorithmic Approach to the Management of PSC and its Complications

Figure 6: 7MM + Nordic Countries Total Diagnosed Prevalent Population of Primary Sclerosing Cholangitis (PSC) (2019–2032)

Figure 7: Total Diagnosed Prevalent Cases of Primary Sclerosing Cholangitis (PSC) in the United States (2019–2032)

Figure 8: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in the United States (2019–2032)

Figure 9: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in the United States (2019–2032)

Figure 10: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in the United States (2019–2032)

Figure 11: Total Diagnosed Prevalent Cases of Primary Sclerosing Cholangitis (PSC) in the EU-5 (2019–2032)

Figure 12: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Germany (2019–2032)

Figure 13: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Germany (2019–2032)

Figure 14: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Germany (2019–2032)

Figure 15: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in France (2019–2032)

Figure 16: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in France (2019–2032)

Figure 17: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in France (2019–2032)

Figure 18: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Italy (2019–2032)

Figure 19: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Italy (2019–2032)

Figure 20: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Italy (2019–2032)

Figure 21: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Spain (2019–2032)

Figure 22: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Spain (2019–2032)

Figure 23: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Spain (2019–2032)

Figure 24: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in the United Kingdom (2019–2032)

Figure 25: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in the United Kingdom (2019–2032)

Figure 26: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in the United Kingdom (2019–2032)

Figure 27: Total Diagnosed Prevalent Cases of Primary Sclerosing Cholangitis (PSC) in Nordic Countries (2019–2032)

Figure 28: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Sweden (2019–2032)

Figure 29: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Sweden (2019–2032)

Figure 30: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Sweden (2019–2032)

Figure 31: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Finland (2019–2032)

Figure 32: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Finland (2019–2032)

Figure 33: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Finland (2019–2032)

Figure 34: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Denmark (2019–2032)

Figure 35: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Denmark (2019–2032)

Figure 36: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Denmark (2019–2032)

Figure 37: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Norway (2019–2032)

Figure 38: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Norway (2019–2032)

Figure 39: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Norway (2019–2032)

Figure 40: Total Diagnosed Prevalent Cases of Primary Sclerosing Cholangitis (PSC) in Japan (2019–2032)

Figure 41: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Japan (2019–2032)

Figure 42: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Japan (2019–2032)

Figure 43: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Japan (2019–2032)

Figure 44: Mechanism of Action of CM-101

Figure 45: 7MM + Nordic Countries Market Size of Primary Sclerosing Cholangitis (PSC) in USD million (2019–2032)

Figure 46: Total Market Size of Primary Sclerosing Cholangitis (PSC) in the United States in USD million (2019–2032)

Figure 47: Market Size of Primary Sclerosing Cholangitis (PSC) in the United States by Therapies in USD million (2019–2032)

Figure 48: Total Market Size of Primary Sclerosing Cholangitis (PSC) in the EU-5 in USD million (2019–2032)

Figure 49: Market Size of Primary Sclerosing Cholangitis (PSC) in Germany by Therapies in USD million (2019–2032)

Figure 50: Market Size of Primary Sclerosing Cholangitis (PSC) in France by Therapies in USD million (2019–2032)

Figure 51: Market Size of Primary Sclerosing Cholangitis (PSC) in Italy by Therapies in USD million (2019–2032)

Figure 52: Market Size of Primary Sclerosing Cholangitis (PSC) in Spain by Therapies in USD million (2019–2032)

Figure 53: Market Size of Primary Sclerosing Cholangitis (PSC) in the United Kingdom by Therapies in USD million (2019–2032)

Figure 54: Total Market Size of Primary Sclerosing Cholangitis (PSC) in Nordic Countries in USD million (2019–2032)

Figure 55: Market Size of Primary Sclerosing Cholangitis (PSC) in Sweden by Therapies in USD million (2019–2032)

Figure 56: Market Size of Primary Sclerosing Cholangitis (PSC) in Finland by Therapies in USD million (2019–2032)

Figure 57: Market Size of Primary Sclerosing Cholangitis (PSC) in Denmark by Therapies in USD million (2019–2032)

Figure 58: Market Size of Primary Sclerosing Cholangitis (PSC) in Norway by Therapies in USD million (2019–2032)

Figure 59: Total Market Size of Primary Sclerosing Cholangitis (PSC) in Japan in USD million (2019–2032)

Figure 60: Market Size of Primary Sclerosing Cholangitis (PSC) in Japan by Therapies in USD million (2019–2032)

Figure 61: A Proposed Roadmap for Developing Validated Surrogate Biomarkers

Gilead Sciences
Phenex Pharmaceuticals
HighTide Therapeutics
Dr. Falk Pharma
Mirum Pharmaceuticals
Pliant Therapeutics, Inc
NGM Biopharmaceuticals
CymaBay Therapeutics
Chemomab Therapeutics

 

Forward to Friend

Need A Quote